ClinicalTrials.gg
CompletedNCT06091020PaiNTUpdated May 5, 2026

A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury

A Phase 2 interventional study of IncobotulinumtoxinA and Placebo in Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury, sponsored by Merz Therapeutics GmbH. Completed at 31 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Merz Therapeutics GmbH (part of Merz Pharma) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 6 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in May 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Neuralgia, Postherpetic with a site in Poland — none open to participants now, none under way, none of them phase 3. Neuralgia, Postherpetic · Poland.

Enrollment
10th of 11
123 · median 280
Started
2023
the only one that year
Phase 2
7 of 11
none open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Merz Therapeutics GmbH

Among the 11 studies in Neuralgia, Postherpetic with a site in Poland, this one is the 10th largest by enrollment, is the only one that started in 2023, is one of 7 in phase 2, and was the 11th registered.

Neuralgia, Postherpetic

197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.

Browse Neuralgia, Postherpetic studies →

Open to participants now

None of the 11 studies in Neuralgia, Postherpetic with a site in Poland is open now. The open studies under Neuralgia, Postherpetic, anywhere →

Who these studies take

Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Neuralgia, Postherpetic with a site in Poland as a file.
02

Study summary

In this clinical trial, participants with nerve pain after shingles or nerve injury will receive injections with NT 201 or placebo. The purpose is to measure the decrease of nerve pain with NT 201 compared to placebo.

Trial details include:

  • Trial duration: 22-23 weeks;
  • Treatment duration: 1 injection visit with a 20-week follow-up period;
  • Visit frequency: 2 remote visits by phone/video call (1 week and 12 weeks after the injection); 2 on-site visits (6 weeks and 20 weeks after the injection).
03

Conditions studied

  • Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic peripheral neuropathic pain that persists for at least 6 months by the time of the screening visit and is plausibly related to either an episode of herpes zoster or a peripheral nerve injury (caused by surgery or mechanical trauma).
  • Documented diagnosis of either chronic neuropathic pain after peripheral nerve injury (i.e., postsurgical/post-traumatic neuropathic pain) or postherpetic neuralgia with at least probable level of certainty according to the NeuPSIG/IASP (Neuropathic Pain Special Interest Group / International Association on the Study of Pain) grading system.
  • A score of at least 4 out of 10 points on the Neuropathic Pain 4 Questions (DN4) questionnaire.

Exclusion criteria

Exclusion Criteria:

  • Complex Regional Pain Syndrome Type 1 and Type 2.
  • Any other painful condition or disease that requires treatment (only mild to moderate episodic migraine treated with triptans and/or non-steroidal anti- inflammatory drugs (NSAIDs), if any, is acceptable).
  • Postsurgical/post-traumatic neuropathic pain due to amputation and/or phantom limb pain.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    NT 201

    Subcutaneous injections of up to 300 units NT 201 into the peripheral neuropathic pain area

    Biological: IncobotulinumtoxinA

  • Placebo comparator
    Placebo

    Subcutaneous injections of placebo into the peripheral neuropathic pain area

    Biological: Placebo

Interventions

  • Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)

    Also known as: Xeomin, Botulinum toxin type A (150 kiloDalton), free from complexing proteins, NT 201

  • BiologicalPlacebo

    Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

06

What researchers measure

Primary outcomes

  1. Weekly averages of changes from baseline in Average Daily Pain (ADP) intensity at Weeks 2 to 12.

    Time frame: Baseline to week 2 to 12

Secondary outcomes

  1. Changes from baseline in Neuropathic Pain Symptom Inventory (NPSI) total score at Weeks 2 to 12

    Time frame: Baseline to week 2 to 12

  2. Incidence of treatment-emergent adverse events (TEAEs) related to study intervention as assessed by the investigator from intervention to end of study.

    Time frame: Baseline to week 20

07

Study locations

31 sites
  • Merz Investigational Site #3590004
    Plovdiv, 4000, Bulgaria
  • Merz Investigational Site #3590006
    Sofia, 1113, Bulgaria
  • Merz Investigational Site #3590005
    Sofia, 1606, Bulgaria
  • Merz Investigational Site #3590002
    Sofia, 1784, Bulgaria
  • Merz Investigational Site #3590003
    Veliko Tarnovo, 5000, Bulgaria
  • Merz Investigational Site #0330066
    Boulogne-Billancourt, 92100, France
  • Merz Investigational Site #0330065
    Limoges, 87042, France
  • Merz Investigational Site #0330067
    Nîmes, 30029, France
  • Merz Investigational Site #0490174
    Essen, 45147, Germany
  • Merz Investigational Site #0490386
    Frankfurt, 60313, Germany
  • Merz Investigational Site #0490389
    Hamburg, 20095, Germany
  • Merz Investigational Site #0490388
    Kiel, 24105, Germany
  • Merz Investigational Site #0490219
    Leipzig, 04103, Germany
  • Merz Investigational Site #0490387
    Westerstede, 26655, Germany
  • Merz Investigational Site #0360021
    Budapest, H-1036, Hungary
  • Merz Investigational Site #0360020
    Budapest, H-1122, Hungary
  • Merz Investigational Site #0360022
    Budapest, H-1145, Hungary
  • Merz Investigational Site #0480113
    Częstochowa, 42-202, Poland
  • Merz Investigational Site #0480112
    Gdynia, 81-537, Poland
  • Merz Investigational Site #0480111
    Katowice, 40-040, Poland
  • Merz Investigational Site #0480115
    Katowice, 40-282, Poland
  • Merz Investigational Site #0480059
    Krakow, 30-539, Poland
  • Merz Investigational Site #0480114
    Lublin, 20-078, Poland
  • Merz Investigational Site #0480110
    Poznan, 60-702, Poland
  • Merz Investigational Site #0480109
    Warsaw, 00-710, Poland
  • Merz Investigational Site #0480107
    Warsaw, 02-672, Poland
  • Merz Investigational Site #0480108
    Wroclaw, 50-381, Poland
  • Merz Investigational Site #0340043
    Barcelona, 08035, Spain
  • Merz Investigational Site #0340044
    Córdoba, 14029, Spain
  • Merz Investigational Site #0340041
    L'Hospitalet de Llobregat, 08907, Spain
  • Merz Investigational Site #0340042
    Seville, 41013, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in May 2025, 17 months.

Of 12 phase 2 interventional studies under Neuralgia, Postherpetic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 17 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2023
First posted
Oct 19, 2023
StartActual
Nov 22, 2023
Primary completionActual
May 7, 2025
CompletionActual
Jul 4, 2025
Results delay requested
May 4, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06091020
Responsible party
Sponsor
First posted
Oct 19, 2023
Start date
Nov 22, 2023
Primary completion
May 7, 2025
Completion
Jul 4, 2025
Last update
May 5, 2026

Study contacts

Merz Medical Expert
study director · Merz Therapeutics GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion